Mersana Therapeutics Inc Sustainability Reports

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes proprietary platforms to engineer targeted immunoconjugates aimed at improving clinical outcomes for cancer patients.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 529900VWD5VDZ7PVOS22

3 reports from 2021 to 2024

• Mersana Therapeutics Inc 2024 Annual Report to Stockholders
• Mersana Therapeutics Inc 2022 Annual Report to Stockholders
• Mersana Therapeutics Inc 2021 Form 10-K